Intervacc
1.01
SEK
-16.53 %
IVACC
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
-16.53%
-62.31%
-72.25%
-69.39%
-84.04%
-85.53%
-97.83%
-92.82%
-84.34%
Intervacc is a biotechnology company. The company develops vaccines within animal health care. There is a special focus on the treatment of infections caused by streptococci and staphylococci. The business is run on the basis of various subsidiaries, each with a business focus. Sales take place mainly in the Nordic and Baltic countries. The company's head office is located in Hägersten.
Read moreMarket cap
76.49M SEK
Turnover
1.16M SEK
Revenue
8.02M
EBIT %
-1,166.83 %
P/E
-
Dividend yield-%
-
Financial calendar
31.1
2025
Extraordinary general meeting '24
13.2
2025
Annual report '24
ShowingAll content types
The Board of Directors of Intervacc resolves on a rights issue of approximately SEK 225 million
Intervacc: Strangvac is back in stock on all launched markets
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools